Notification of request for a time-limited exemption to continue batch control testing in the United Kingdom (UK) after UK’s withdrawal from the Union for a nationally authorised medicinal product

Invented name of medicinal product\*: …

*\*NB: In case of an MRP/DCP products only the product name in the RMS should be included*

DCP/MRP procedure number:

National licence number (in case of a product purely nationally authorised i.e. not through MR/DCP):

Marketing authorisation (MA) holder\* name and address: …

*\*NB: In case of an MRP/DCP products only the MAH in the RMS should be included here (see also declaration below)*

With reference to the published communication from the European Commission dated 21/02/2019, we herewith request a time-limited exemption to continue batch control testing in the UK after 29th March 2019 for the above mentioned nationally authorised medicinal product(s) with the following scope:

1. **Batch release site(s) identified in EU27/EEA**

|  |
| --- |
| Company name (batch release site): …  Address of the site: …  Country: …  EudraGMDP reference number of manufacturing authorisation: …  If the site has been recently added and is not yet reflected in the MA, please indicate the procedure number for introducing the site in the MA (where available) or imminent planned submission date: … |

*Note: Please copy the above table in case of multiple batch release sites*

1. **Current batch control site(s) in UK**

|  |
| --- |
| Company name (batch control site in UK): …  Address of the site: …, UK  Finished product specification parameters tested at the site[[1]](#footnote-1): … |

*Note: Please copy the above table in case of multiple batch control sites in the UK*

1. **Timelines for implementation of the (new) batch control testing in the EU27/EEA**

|  |  |  |
| --- | --- | --- |
| Name of the new EU27/EEA site for batch control testing for release: …  Address of the site: …  Country: …  EudraGMDP reference number of manufacturing authorisation or GMP certificate (if available): …  For biological products, finished product specification parameters to be tested at this site: … | | |
| *Activities for transfer of batch control testing* | *Planned date of completion* | *Short justification for the time required* |
| <Specify main steps needed for transfer of testing. Include additional rows as needed.> | … | … |
| … | … | … |
| **Implementation of testing at this site** | **…** | … |
| **For biological products: submission of respective variation application[[2]](#footnote-2)** | **…** | Planned variation type: … |

*Note: Please copy the above table in case multiple batch control sites in EU27/EEA will be used for the specifications/tests to be transferred.*

**End date of the requested exemption: …[[3]](#footnote-3)**

1. **Confirmation**

**We herewith declare that** (please confirm all of the following by using the tick-boxes):

The Qualified Person(s) of the EU27/EEA batch release site(s) indicated above is(/are) established in EU27/EEA and is (/are) responsible for ensuring that the quality control testing at the site(s) in the UK is conducted in accordance with EU GMP and the requirements of the Marketing Authorisation;

Upon request, we will provide to the relevant EU27/EEA national competent authorities batch testing results from the facilities within the UK for the batches to be released under this exemption;

Test results will be provided to the Qualified Person(s) of the EU27/EEA batch release site(s) prior to certification and release of batches under this exemption. The associated reference / retention samples for these batches will, in due time, be transferred to an authorised site within the EU27/EEA and will be made available for inspection;

We have taken necessary steps to prepare for transfer of the quality control testing and the timelines indicated above do not exceed the time needed to implement batch release testing in the EU27/EEA;

We will record information on individual batches released under this exemption and, upon request, will provide it to the relevant EU27/EEA national competent authorities;

Currently there is no batch control site in the EU27/EEA authorised for batch control testing activities subject to this request (as detailed in sections 2 and 3).

󠄁For MR/DCP procedures we declare that this exemption is submitted on behalf of all MAHs in the CMS’s

Date: …

*On behalf of the marketing authorisation holder:* \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

*Signature and printed name of the authorised contact person*

1. Include only those tests that cannot be conducted in a (potential) already approved alternative testing site in EU27/EEA [↑](#footnote-ref-1)
2. For biological products a type IB or type II variation has to be submitted (depending on the test methods transferred) and completed before the implementation. [↑](#footnote-ref-2)
3. Transfer of all batch release testing must be completed by this date and medicinal products not tested in EU27/EEA site(s) cannot be placed on EU27/EEA market after this date. This should be the earliest date possible but in any case no later than 31st December 2019. [↑](#footnote-ref-3)